---
document_datetime: 2025-08-14 16:49:53
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imjudo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imjudo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5423612
conversion_datetime: 2025-12-24 16:53:42.427136
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IMJUDO

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11038 /202410  | Periodic Safety Update EU Single assessment - tremelimumab | 22/05/2025                          | 04/08/2025                                  |                                  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11038/202410. |
| PSUSA/11038 /202404  | Periodic Safety Update EU Single assessment - tremelimumab | 12/12/2024                          | 14/02/2025                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                     |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             | PSUSA/11038/202404.   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| N/0011      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11/12/2024 | 14/02/2025 | PL          |                       |
| IB/0010/G   | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 09/10/2024 | n/a        |             |                       |
| IAIN/0008/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/07/2024 | 14/02/2025 | SmPC and PL |                       |

<div style=\"page-break-after: always\"></div>

| IA/0007             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                    | 09/07/2024   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2650             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.2 and 4.4 of the SmPC in order to simplify current dosing recommendations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/04/2024   | 27/05/2024 | SmPC        | SmPC new text In section 4.4, for Grade 3 or 4 events of immune- mediated pneumonitis, an initial dose of 2-4 mg/kg/day methylprednisolone or equivalent should be initiated followed by a taper. For Immune-mediated colitis/diarrhea, a footnote is included in Table 2 to clarify that in Grade 3 events for patients on IMFINZI + tremelimumab, tremelimumab is to be permanently discontinued while durvalumab can be resumed once the event has resolved. For more information, please refer to the Summary of |
| PSUSA/11038 /202310 | Periodic Safety Update EU Single assessment - tremelimumab                                                                                                                                                                                                                                                                                                     | 16/05/2024   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/11038 /202304 | Periodic Safety Update EU Single assessment - tremelimumab                                                                                                                                                                                                                                                                                                     | 14/12/2023   | 16/02/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11038/202304.                                                                                                                                                                                                                                                                                                                                                                           |
| WS/2543             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to include paediatric information based on final results from study D419EC00001 'Phase I/II, Open- Label, Multicenter Study to Evaluate the Safety,     | 14/12/2023   | 16/02/2024 | SmPC        | Based on the results from study D419EC00001 in children and adolescents, sections 4.2, 5.1, and 5.2 have been updated. The efficacy and safety of of durvalumab in combination with tremelimumab in children were assessed but not established. Currently available data are reported in the SmPC. In the dose-expansion phase, an Overall Response Rate of 5.0% (1/20 patients) was reported in the evaluable for response analysis set. No new safety signals                                                      |

<div style=\"page-break-after: always\"></div>

|         | Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies'. In addition, the MAH took this opportunity to introduce editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        | were observed relative to the known safety profiles of durvalumab and tremelimumab in adults. For more information, please refer to the Summary of Product Characteristics.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1659 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 04/09/2023 | 16/02/2024 | Annex II and PL        |                                                                                                                                                                               |
| II/0001 | Extension of indication to include in combination with durvalumab and platinum-based chemotherapy, the first-line treatment of adults with metastatic non- small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations for Imjudo, based on the final analysis from the pivotal study D419MC00004, a Randomised, Multi-center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Patients with Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON). As a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to include minor editorial changes. | 22/06/2023 | 04/08/2023 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Imjudo-H-C-6016-II- 0001'                                                                                                              |

<div style=\"page-break-after: always\"></div>

| The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet.   | C.I.6.a - Change(s) Addition of modification   |
|----------------------------------------------------------------------------------------------------|------------------------------------------------|